Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the ...

Common viral respiratory infections such as COVID-19, respiratory syncytial virus (RSV) and influenza are linked to an ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...